Nek2 and Plk4: Prognostic Markers, Drivers of Breast Tumorigenesis and Drug Resistance

Overview

Journal Front Biosci (Landmark Ed)

Specialty Biology

Date 2014 Jan 7

PMID 24389189

Citations 64

Authors

Mihaela Marina

Harold I Saavedra

Affiliations

Soon will be listed here.

Abstract

The Nek2 and Plk4 kinases serve as crucial regulators of mitotic processes such as the centrosome duplication cycle and spindle assembly. Deregulation of these processes can trigger chromosome instability and aneuploidy, which are hallmarks of many solid tumors, including breast cancer. Emerging data from the literature illustrated various functions of Nek2 in breast cancer models, with compelling evidence of its prognostic value in breast tumors. The two kinases control distinct steps in the centrosome-centriole cycle and their dysregulation lead to centrosome amplification, marked by the presence of more than two centrosomes within the cell. We found single or composite overexpression of these kinases in breast tumor samples, regardless of subtype, which strongly associated with poor prognosis. Interestingly, in a panel of established cell lines, both kinases are highly expressed in Her2-positive breast cancer cells exhibiting centrosome amplification and trastuzumab resistance. In summary, it appears that Nek2 and Plk4 might synergize to promote breast tumorigenesis and may also be involved in tamoxifen and trastuzumab resistance.

Citing Articles

NEK2 Phosphorylates RhoGDI1 to Promote Cell Proliferation, Migration and Invasion Through the Activation of RhoA and Rac1 in Colon Cancer Cells.

Lim J, Hwang Y, Kim J, Yoon H, Park H, Han J Cells. 2025; 13(24.

PMID: 39768163 PMC: 11674122. DOI: 10.3390/cells13242072.

Bystanders or active players: the role of extra centrosomes as signaling hubs.

Purkerson M, Amend S, Pienta K Cancer Metastasis Rev. 2024; 44(1):1.

PMID: 39570514 PMC: 11582193. DOI: 10.1007/s10555-024-10224-4.

Mitotic kinases are emerging therapeutic targets against metastatic breast cancer.

Aquino-Acevedo A, Orengo-Orengo J, Cruz-Robles M, Saavedra H Cell Div. 2024; 19(1):21.

PMID: 38886738 PMC: 11184769. DOI: 10.1186/s13008-024-00125-x.

Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.

Athwal H, Kochiyanil A, Bhat V, Allan A, Parsyan A Front Oncol. 2024; 14:1370565.

PMID: 38606093 PMC: 11007099. DOI: 10.3389/fonc.2024.1370565.

Seize the engine: Emerging cell cycle targets in breast cancer.

Fuentes-Antras J, Bedard P, Cescon D Clin Transl Med. 2024; 14(1):e1544.

PMID: 38264947 PMC: 10807317. DOI: 10.1002/ctm2.1544.

References

Maire V, Nemati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G . Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 2012; 73(2):813-23. DOI: 10.1158/0008-5472.CAN-12-2633. View

Frogne T, Jepsen J, Larsen S, Fog C, Brockdorff B, Lykkesfeldt A . Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer. 2005; 12(3):599-614. DOI: 10.1677/erc.1.00946. View

Fukasawa K . Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer. 2007; 7(12):911-24. DOI: 10.1038/nrc2249. View

Doxsey S, Zimmerman W, Mikule K . Centrosome control of the cell cycle. Trends Cell Biol. 2005; 15(6):303-11. DOI: 10.1016/j.tcb.2005.04.008. View

Korzeniewski N, Hohenfellner M, Duensing S . CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia. 2012; 14(9):799-806. PMC: 3459275. DOI: 10.1593/neo.12580. View

Olson J, Wang X, Pankratz V, Fredericksen Z, Vachon C, Vierkant R . Centrosome-related genes, genetic variation, and risk of breast cancer. Breast Cancer Res Treat. 2010; 125(1):221-8. PMC: 2997159. DOI: 10.1007/s10549-010-0950-8. View

Leontovich A, Salisbury J, Veroux M, Tallarita T, Billadeau D, McCubrey J . Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. Oncol Rep. 2013; 29(5):1785-8. PMC: 3658847. DOI: 10.3892/or.2013.2313. View

Ghayad S, Vendrell J, Ben Larbi S, Dumontet C, Bieche I, Cohen P . Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2009; 126(2):545-62. DOI: 10.1002/ijc.24750. View

Guo H, Gao M, Ma J, Xiao T, Zhao L, Gao Y . Analysis of the cellular centrosome in fine-needle aspirations of the breast. Breast Cancer Res. 2007; 9(4):R48. PMC: 2206724. DOI: 10.1186/bcr1752. View

10.

Fujiwara T, Bandi M, Nitta M, Ivanova E, Bronson R, Pellman D . Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 2005; 437(7061):1043-7. DOI: 10.1038/nature04217. View

11.

Arpino G, Wiechmann L, Osborne C, Schiff R . Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29(2):217-33. PMC: 2528847. DOI: 10.1210/er.2006-0045. View

12.

Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M . Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res. 2008; 68(3):767-76. DOI: 10.1158/0008-5472.CAN-07-5516. View

13.

Pihan G, Wallace J, Zhou Y, Doxsey S . Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003; 63(6):1398-404. View

14.

Le X, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K . Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle. 2006; 5(15):1654-61. DOI: 10.4161/cc.5.15.3007. View

15.

Fu G, Ding X, Yuan K, Aikhionbare F, Yao J, Cai X . Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis. Cell Res. 2007; 17(7):608-18. DOI: 10.1038/cr.2007.55. View

16.

Berezovska O, Glinskii A, Yang Z, Li X, Hoffman R, Glinsky G . Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006; 5(16):1886-901. DOI: 10.4161/cc.5.16.3222. View

17.

Brodie K, Henderson B . Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem. 2012; 287(10):7701-16. PMC: 3293534. DOI: 10.1074/jbc.M111.327296. View

18.

Tarapore P, Horn H, Tokuyama Y, Fukasawa K . Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene. 2001; 20(25):3173-84. DOI: 10.1038/sj.onc.1204424. View

19.

Montagna C, Andrechek E, Padilla-Nash H, Muller W, Ried T . Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene. 2002; 21(6):890-8. DOI: 10.1038/sj.onc.1205146. View

20.

Bieche I, Vacher S, Lallemand F, Tozlu-Kara S, Bennani H, Beuzelin M . Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. Mol Cancer. 2011; 10:23. PMC: 3058099. DOI: 10.1186/1476-4598-10-23. View